The "LAG-3 Antagonist – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering. This "LAG-3 Antagonist – Pipeline Insight, 2021," report provides comprehensive ...
Contineum Therapeutics, Inc. (CTNM) has been able to do well to advance the use of an LPA1R antagonist for the treatment of neuroinflammatory disorders in a phase 1 healthy volunteer study. Why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback